By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment bank Goldman Sachs this week lowered its earnings-per-share estimates for Qiagen as well as its six-month price target on the firm's stock. The bank revised its estimates following the recent completion of Qiagen's acquisition of Cellestis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.